Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism

Abstract

People with venous thromboembolism are generally treated for five days with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin followed by three months of vitamin K antagonists treatment. Treatment with vitamin K antagonists requires regular laboratory measurements and some patients have contraindications for treatment.